sonolisib
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT00726583)
Timeline
Indications
Mechanism of action
- PI3-kinase class IINHIBITOR
PI3-kinase class I inhibitor
- Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) ↗
- Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) ↗
- Phosphoinositide 3-kinase regulatory subunit 5 (PIK3R5) ↗
- Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3) ↗
- PI3-kinase p85-alpha subunit
- PI3-kinase p110-delta subunit
- PI3-kinase p110-alpha subunit
- PI3-kinase p110-gamma subunit
- PI3-kinase p110-beta subunit
- PI3-kinase p85-beta subunit
- PI3-kinase p110-delta/p85-alpha
- PI3-kinase p110-alpha/p85-alpha
- PI3K p110 beta/p85 alpha
- PI3-kinase subunit gamma/Phosphoinositide 3-kinase regulatory subunit 5
- Phosphatidylinositol 3-kinase regulatory subunit beta/Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform
- PIK3CG/PIK3R1
- Phosphatidylinositol 3-kinase regulatory subunit gamma
Chemistry & pharmacology
Loading structure…
SMILES
C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C- Mol. weight
- 525.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL411907 ↗
Also known as
- px-866
- px-866
- px-866
- sonolisib
- sonolisib
- sonolisib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01616199 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | Cascadian Therapeutics Inc. |
| NCT01408316 | Phase 1 | Jul 1, 2011 | Cascadian Therapeutics Inc. |
| NCT01331083 | Phase 2 | May 1, 2011 | British Columbia Cancer Agency, Canadian Cancer Trials Group, Cascadian Therapeutics Inc., McMaster University |
| NCT01259869 | Phase 2 | Jan 1, 2011 | Canadian Cancer Trials Group, CancerCare Manitoba, Cascadian Therapeutics Inc. |
| NCT01252628 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | Cascadian Therapeutics Inc. |
| NCT01204099 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2010 | Cascadian Therapeutics Inc. |
| NCT00726583 | Phase 1 | Jun 1, 2008 | Cascadian Therapeutics Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cascadian Therapeutics Inc. | For profit | 7 | 5 | 2 | 2008 |
| Canadian Cancer Trials Group | Academic/Hospital | 2 | 2 | 1 | 2011 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2011 |
| CancerCare Manitoba | Academic/Hospital | 1 | 0 | 1 | 2011 |
| McMaster University | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1